Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine

Publication year - 2020

Publication title -

medical and clinical research

Language(s) - English

Resource type - Journals

ISSN - 2577-8005

DOI - 10.33140/mcr.05.11.03

Subject(s) - lamivudine , entecavir , adefovir , telbivudine , tenofovir alafenamide , virology , medicine , hepatocellular carcinoma , hepatitis b , emtricitabine , hepatitis b virus , viral load , virus , antiretroviral therapy

Hepatitis B virus (HBV) is a significant global health problem with more than 350 million people chronically infected. Currently it is believed that HBV is responsible for 50% of hepatocellular carcinoma (HCC) worldwide [1-3]. While a cure for HBV is still needed, several oral drugs that suppress viral replication exist. In the United States, six nucleos(t)ide analogues that have been approved at different time periods include lamivudine (1998), adefovir (2002), entecavir (2005), telbivudine (2006), tenofovir disoproxil fumarate (2008) and tenofovir alafenamide (2016).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research